Mendus Logo

Mendus

Developing immunotherapies using dendritic cells to prevent cancer recurrence and improve survival.

IMMU | ST

Overview

Corporate Details

ISIN(s):
SE0005003654 (+1 more)
LEI:
529900AFBGFR7ZB50J95
Country:
Sweden
Address:
Västra Trädgårdsgatan 15, 111 53 Stockholm
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Mendus is a clinical-stage biotechnology company dedicated to developing immunotherapies for cancer treatment. The company focuses on preventing tumor recurrence by stimulating the patient's immune system to build active immunity against residual cancer cells. Specializing in allogeneic dendritic cell biology, Mendus aims to improve long-term survival outcomes and preserve the quality of life for cancer patients. Its lead product candidate, vididencel, is under development for various malignancies, including ovarian cancer.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-02 08:00
Regulatory News Service
Mendus meddelar uppdaterad klinisk strategi och operativt fokus
Swedish 138.6 KB
2025-10-02 08:00
Regulatory News Service
Mendus announces updated clinical strategy and operational focus
English 137.5 KB
2025-08-21 08:00
Quarterly Report
Swedish 1.4 MB
2025-08-21 08:00
Quarterly Report
English 1.4 MB
2025-08-20 18:00
Transaction in Own Shares
Mendus AB (publ) has resolved to transfer own shares on Nasdaq Stockholm
English 117.2 KB
2025-08-20 18:00
Transaction in Own Shares
Mendus AB (publ) har beslutat om överlåtelse av egna aktier
Swedish 117.4 KB
2025-06-30 08:00
Declaration of Voting Results & Voting Rights Announcements
Ändring av antalet aktier och röster i Mendus AB (publ)
Swedish 124.2 KB
2025-06-30 08:00
Share Issue/Capital Change
Change in number of shares and votes in Mendus AB (publ)
English 123.6 KB
2025-05-26 17:50
Remuneration Information
Mendus AB (publ) har beslutat om emission av C-aktier och överlåtelse av egna s…
Swedish 117.6 KB
2025-05-26 17:50
Share Issue/Capital Change
Mendus AB (publ) has decided on directed issues of Class C shares and transfer …
English 118.1 KB
2025-05-06 10:10
Post-Annual General Meeting Information
Kommuniké från årsstämma i Mendus AB (publ) den 6 maj 2025
Swedish 128.6 KB
2025-05-06 10:10
Post-Annual General Meeting Information
Report from the Annual General Meeting of Mendus AB (publ) on 6 May 2025
English 128.9 KB
2025-05-06 08:00
Earnings Release
Swedish 1.4 MB
2025-05-06 08:00
Quarterly Report
English 1.4 MB
2025-02-13 08:00
Earnings Release
Swedish 1.5 MB

Automate Your Workflow. Get a real-time feed of all Mendus filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Mendus via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-03-11 Erik Manting Other Buy 7,780 56,249.40 SEK
2025-03-11 Erik Manting Other Buy 7,780 55,704.80 SEK
2025-02-25 Sven Arne Andreasson Other Buy 25,000 198,750.00 SEK
2024-04-02 Erik Manting Other Other 885,648 425,111.04 SEK
2024-04-02 Dharminder Chahal Other Other 882,048 423,383.04 SEK
2024-04-02 Leopold Bertea Other Other 267,858 128,571.84 SEK
2022-10-25 Sven Arne Andreasson Other Sell 15,000 31,950.00 SEK
2022-10-12 Sven Arne Andreasson Other Sell 10,000 18,800.00 SEK
2022-05-20 Erik Manting Other Buy 37,059 86,347.47 SEK
2022-05-19 Ann-Charlotte Ferm Other Buy 100,000 215,900.00 SEK

Peer Companies

Company Country Ticker View
Optipharm.CO.,LTD Logo
Biotech for animal health and xenotransplantation using genetically engineered pig organs.
South Korea 153710
Organoid-based platforms for drug testing and regenerative therapeutics.
South Korea 476040
Oricon Inc. Logo
Provides entertainment industry data, music charts, web media, and marketing services.
Japan 4800
ORIENTBIO Inc. Logo
Provides animal models & technical services for preclinical R&D to pharma & research institutions.
South Korea 002630
Oryzon Genomics S.A. Logo
Develops epigenetic-based medicines for cancer and central nervous system disorders.
Spain ORY
OSCOTECInc. Logo
A clinical-stage drug discovery company developing innovative medicines for unmet needs.
South Korea 039200
OSE Immunotherapeutics Logo
Develops first-in-class immune therapies for oncology and inflammation, partnering for late-stage.
France OSE
Oxurion NV Logo
Acquires European pharmaceutical subcontractors to build an integrated healthcare services group.
Belgium OXUR
PA Co., Ltd Logo
Offers HR solutions like recruitment media, staffing, and childcare to revitalize local communities.
Japan 4766
PCI Biotech Holding Logo
Biopharma firm evaluating its future after discontinuing its core technology development.
Norway PCIB

Talk to a Data Expert

Have a question? We'll get back to you promptly.